Loading…

Incidental detection of oropharyngeal cancer with fluciclovine PET

Background Fluorine‐18‐labeled 1‐amino‐3‐fluorocyclobutane‐1‐carboxylic acid (fluciclovine) is a synthetic amino acid radiopharmaceutical initially developed to improve noninvasive diagnosis of gliomas and currently FDA approved for prostate cancer imaging. Although fluciclovine positron emission to...

Full description

Saved in:
Bibliographic Details
Published in:Head & neck 2019-08, Vol.41 (8), p.E141-E145
Main Authors: Jethanandani, Amit, Chen, Melissa M., Gule‐Monroe, Maria K., Morrison, William H., Lai, Stephen Y., Johnson, Jason M.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Fluorine‐18‐labeled 1‐amino‐3‐fluorocyclobutane‐1‐carboxylic acid (fluciclovine) is a synthetic amino acid radiopharmaceutical initially developed to improve noninvasive diagnosis of gliomas and currently FDA approved for prostate cancer imaging. Although fluciclovine positron emission tomography (PET) has proven to be efficacious in detecting multiple types of cancer, its ability to detect oropharyngeal squamous cell carcinoma (OPSCC) is largely unknown. Methods We describe a case of incidental OPSCC detection with fluciclovine PET in a 66‐year old male patient during workup for recurrent prostate adenocarcinoma. Results Fluciclovine PET detected a left base of tongue (BOT) lesion, which was subsequently confirmed as invasive SCC on surgical pathology. Conclusion Given these findings, we discuss potential future directions for research with fluciclovine to overcome some of the known limitations of 18[F]fluorodeoxyglucose in oncological imaging.
ISSN:1043-3074
1097-0347
DOI:10.1002/hed.25798